According to an analysis by Ackrell Capital, the $4.4 billion legal North American marijuana industry is about to explode—detonated by the liberalization of cannabis laws in Canada and the US.
With the baby boomers creaking, diabetes rates, arthritis and cancer are now skyrocketing. According to the Center for Disease control and Prevention, 50% of all adults in North America have suffered one or more chronic health conditions. The market for chronic pain medication is at the leading edge of a long term growth phase. Physicians and consumers are searching for alternatives to conventional opioids which are addictive and vulnerable to abuse.
Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is applying real science to medical marijuana development, production and branding. The company is driving shareholder value with a low cost R&D model, estimated at one-tenth the time of traditional pharma drug approval.
Veritas has invested in its R&D arm, Cannevert Therapeutics, a Vancouver company aiming to discover new cannabis strains for specific disease conditions.
